Universe Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research Center
Universe Pharmaceuticals INC (Nasdaq: UPC) has been authorized as an International Branch of the National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine. This designation allows the Company to leverage the Center's technologies and enhance its focus on traditional Chinese medicine, Kampo medicine, and related products. The Company aims to improve its brand recognition and market position, particularly serving middle-aged and elderly populations. This milestone is viewed as recognition of the Company's capabilities within the traditional Chinese medicine industry.
- Authorized as an International Branch of a recognized research center, enhancing credibility.
- Opportunity to leverage extensive resources and technologies from the Center.
- Focus on developing traditional Chinese medicine products targeting the elderly market.
- None.
Ji’an, Jiangxi, China, March 22, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company has been authorized as an International Branch (the “Branch”) of the National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine (the “Center”), a Chinese medicine industry research center approved by the Ministry of Science and Technology of China. As an authorized International Branch, the Company will be allowed to join the Center’s strong network and share its extensive industrial recourses, and such authorization demonstrates industry’s recognition of the Company's capabilities.
The Company hosted the authorization ceremony and reception for government and industry representatives on March 11, 2022 in Ji’an, China. Participants of this ceremony included Mr. Xiaodong Zhu, Deputy Mayor of Ji’an government, Mr. Runjin Peng, Mayor of the Ji’an county, Mr. Hui Cao, Director of the Center, Mr. Ming Yang, Professor and Vice President of Jiangxi University of Traditional Chinese Medicine, Mr. Gang Lai, Chairman and CEO of the Company, Mr. Yajun Hu, Vice President of the Company, and Mr. Ichiri Nishimura, Foreign Expert of the Company and Director of the Branch.
Through leveraging the Center’s technologies and utilizing the Company's research and development capacity, the Company has determined to focus its research and development efforts on traditional Chinese medicine, Kampo medicine, Chinese medicine formula granules, and Chinese medicine essential oils. The Company strives to enhance its brand recognition and market position as a pharmaceutical company that serves middle-aged and elderly people.
Under the guidance of the Center, the Company expects to implement a series of new measures, integrate resources, and improve communications with other biopharmaceutical companies, and the Company intends to make contributions to the internationalization of traditional Chinese medicine.
Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are excited to be authorized as a Branch from the Center, which is a key milestone for the Company as we are recognized by the experts in the traditional Chinese medicine industry and supported by the Ji’an government. With the integration of resources and support from these parties, we will further work on developing additional types of traditional Chinese medicine and increase our efforts to emerge as a leader in the industry.”
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the Company’s website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For more information, please contact:
Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com
FAQ
What recent milestone did Universe Pharmaceuticals INC achieve?
How will the authorization benefit Universe Pharmaceuticals INC?
What type of products is Universe Pharmaceuticals INC focusing on?
When was the authorization ceremony for Universe Pharmaceuticals INC held?
What is the significance of the partnership with the National Engineering Technology Research Center?
